Endocrine

, Volume 6, Issue 2, pp 203–206 | Cite as

Bisphosphonates in the treatment of osteoporosis

  • Norman H. Bell
  • Ralph H. Johnson
Virtual Symposium on Osteoporosis

Abstract

Bisphosphonates are compounds derived from pyrophosphate, a byproduct of cellular cleavage of adenosine triphosphate (ATP), and are resistant to alkaline phosphatase by virtue of replacement of oxygen by carbon. The high affinity of the P-C-P structure for hydroxyapatite accounts for deposition in bone. Modification of the two side chains of carbon alters the potency of the drugs. Of those that have either completed or are undergoing clinical trials, the order of increasing potency for inhibition of bone resorption is etidronate, clodronate, tiludronate, pamidronate, alendronate, residronate and ibandronate (potency range: 1 to 10,000). Less than 5% of bisphosphonates are absorbed and the half life is a few hours. The drugs must be given on an empty stomach because food and beverages interfere with gastrointestinal absorption. Of the absorbed fraction, as much as 60% is taken up by the skeleton and the remainder is excreted un changed in the urine. Etidronate, tiludronate, residronate, and alendronate are given orally, clodronate intravenously, and pamidronate and ibandronate by either route. At lower concentrations, bisphosphonates inhibit osteoclatic bone resorption, whereas at higher concentrations they may inhibit mineralization and cause osteomalacia. Inhibition of mineralization diminishes with increasing potency. In postmenopausal women, etidronate and alendronate for 3 yr were shown to inhibit bone resorption, increase bone mineral density (BMD) of the lumbar spine and hip, and prevent fractures without producing osteomalacia. Bone formation also is reduced as a consequence of diminished bone resorption but reduction is less than the reduction of bone resorption. In higher doses bisphosphonates may cause upper gastrointestinal disturbances but in recommended doses they generally are well tolerated and have an excellent safety profile.

Key Words

Bisphosphonates bone resorption osteoclasts osteoporosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fleisch, H. (1981).Metab. Bone. Dis. Rel. Res. 4, 279–288.CrossRefGoogle Scholar
  2. 2.
    Fleisch, H. (1995). InBisphosphonates in Bone Disease: from the Laboratory to the Patient. 2nd. ed. The Parthenon Publishing Group: New York.Google Scholar
  3. 3.
    Fleisch, H. (1991).Drugs 42, 919–944.PubMedGoogle Scholar
  4. 4.
    DeGroen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., and Wang, K. K. (1996).N. Engl. J. Med. 335, 1018–1021.CrossRefGoogle Scholar
  5. 5.
    Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., and Martin, T. J. (1993).J. Clin. Invest. 91, 2004–2011.PubMedCrossRefGoogle Scholar
  6. 6.
    Green, J. R., Muller, K., and Jaeggi, K. A. (1994).J. Bone Miner. Res. 9, 745–751.PubMedGoogle Scholar
  7. 7.
    Mühlbauer, R. C. (1994). InSex Steroids and Bone. Ziegler, R., Pfeilschifter, J., and Bräutigam, M. (eds.). Springer-Verlag: Heidelberg, pp. 191–202.Google Scholar
  8. 8.
    Chesnut, C. H., III, McClung, M. R., Ensrud K. E., Bell, N. H., Genant, K., Harris, S. T., Singer, F. R., Stock, J. L., Yood, R. I., Delmas, P. D., Kher, U., Pryor-Tillotson, S., and Santora, A. C., II. (1995).Am. J. Med. 99, 144–152.PubMedCrossRefGoogle Scholar
  9. 9.
    Liberman, U. A., Weiss, S. R., Broll, J. H., Rodriguez-Portalis, J., Downs, R. W., Seeman, E., Recker, R. R., Capizzi, T., Santora, A., II, and Lombardi, A., Shah, R. V., Hirsch, J. H., and Karpf, D. B. (1995).N. Engl. J. Med. 333, 1437–1443.PubMedCrossRefGoogle Scholar
  10. 10.
    Giannini, S., D’Angelo, A., Malvasi, L., Castrignano, R., Pati, T., Tronca, R., Liberto, L., Nobile, M., and Crepaldi, G. (1993).Bone 14, 137–141.PubMedCrossRefGoogle Scholar
  11. 11.
    Harris, S. T., Watts, N. B., Jackson, R. D., Genant, H. K., Wasnich, R. D., Ross, P., Miller, P. D., Licata, A. A., and Chesnut, C. H., III. (1993).Am. J. Med. 95, 557–567.PubMedCrossRefGoogle Scholar
  12. 12.
    Reid, I. R., Watti, D. J., Evans, M. C., Gamble, G. D., Stapleton, J. P., and Cornish, J. (1994).J. Clin. Endocrinol. Metab. 79, 1595–1599.PubMedCrossRefGoogle Scholar
  13. 13.
    Thiebaud, D., Burckhartd, P., Melchior, J., Eckert, P., Jacquet, A. F., Schnyder, P., and Gobelet, C. (1994).Osteoporosis Int. 4, 76–83.CrossRefGoogle Scholar
  14. 14.
    Landman, J. O., Hamdy, N. A. T., Pauwels, E. K. J., and Papapoulos, S. E. (1995).J. Clin. Endocrinol. Metab. 80, 3465–3468.PubMedCrossRefGoogle Scholar
  15. 15.
    Reginster, J. Y., Lecart, M. P., Deroisy, R., Sarlet, N., Denis, D., Ethgen, D., Collette, J., and Franchimont, P. (1989).Lancet 2, 1469–1471.PubMedCrossRefGoogle Scholar
  16. 16.
    Thompson, D. D., Seedor, J. G., Quartuccio, H., Solomon, H., Fioravanti, C., David, J., Klein, H., Jackson, R., Clair, J., Frankenfield, D., Brown, E., Simmons, H. A., and Rodan, G. A. (1992).J. Bone Miner. Res. 7, 951–960.PubMedCrossRefGoogle Scholar
  17. 17.
    Toolan, B. C., Shea, M., Myers, E. R., Borchers, R. E., Seedor, J. G., Quartuccio, H., Rodan, G. A., and Hayes, W. C. (1993).J. Bone Miner. Res. 7, 1399–1406.Google Scholar

Copyright information

© Humana Press Inc 1997

Authors and Affiliations

  • Norman H. Bell
    • 1
  • Ralph H. Johnson
    • 2
  1. 1.Department of Medicine and Pharmacology, MedicalUniversity of South CarolinaCharleston
  2. 2.Department of Veterans Affairs Medical CenterCharleston

Personalised recommendations